Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha.
about
SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexesSYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histonesSWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcriptionTherapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomasDeconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeuticsReversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcomaThe SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcomaRegulation of plant growth and development by the GROWTH-REGULATING FACTOR and GRF-INTERACTING FACTOR duoConserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomersCo-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomasThe proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteinsIGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathwaySS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic ModifierSYT-SSX1 (synovial sarcoma translocated) regulates PIASy ligase activity to cause overexpression of NCOA3 proteinEpigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.Cytosolic SYT/SS18 isoforms are actin-associated proteins that function in matrix-specific adhesion.Identification of target genes for wild type and truncated HMGA2 in mesenchymal stem-like cells.Animal models of soft-tissue sarcoma.Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas.Notch signaling in pediatric soft tissue sarcomasVorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.Synovial sarcoma: from genetics to genetic-based animal modelingThe SYT-SSX fusion protein and histological epithelial differentiation in synovial sarcoma: relationship with extracellular matrix remodeling.Chromatin modification, leukaemia and implications for therapy.Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.Molecular genetics of pediatric soft tissue tumors: clinical application.SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcomaMolecular target therapy for synovial sarcoma.Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitroPrimary cardiac synovial sarcoma: a case report and brief review of the literature.Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatmentPediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities.Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene.Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells.
P2860
Q21134718-4C124889-9A09-43BA-8B61-C14D9E739866Q24291965-A8DE8FED-A4D3-4E2F-B139-CD01AADC80BEQ24294282-2B4C5C36-D648-472B-9A06-78971B5913A6Q24307530-34157860-6B7F-443C-8353-1834E5B397E0Q24308344-1833E0EF-F1AB-4A1A-B250-ECF4A59ED8A1Q24337483-E60C3F06-7027-4B70-9EC1-FE436A02C44AQ24673690-6D1DDEA3-376A-4E6B-859B-7EAF39202FD1Q28085722-F57848E6-A2EC-4757-96A4-B4ED94BB3055Q28182275-C88B0EE9-523B-4E42-9394-856110DE3432Q28201703-A313B727-236F-450A-AECC-BD7203112C36Q28277223-F42BA00F-2BE0-46CF-B6A0-788E944B5EA5Q28278853-12E573BB-0D37-40C0-9365-27220B4249F6Q28507076-9980582D-FC3C-4E6C-844D-02C60015DE5EQ28550973-CD524D22-1785-4A86-B5C6-A074435A457BQ28568099-498E279B-9280-4096-A238-F3998627AF42Q30914150-022A0B6A-C68C-4896-9F7D-EBD6CEE2E939Q33425217-5D4BABD1-058F-4A25-BEF3-7A4AAC44764DQ33489583-E56A9753-BB09-4181-8D7E-0E70984CAEE9Q33615450-57175C24-423F-4C12-8F74-3D40B41A5390Q34098113-D040B710-52B3-4412-B67C-530AA1DC06A3Q34312526-33D4C254-C0C3-4527-9E71-FA137FD7545BQ34480012-F1636E4A-76E0-4275-8A1C-90671470B107Q34587139-B0C18FF2-D12A-4BC4-A1BD-0FA878ACF243Q34593303-108C1BA6-86B0-43BB-931A-F2F70AA1408FQ34657445-7EE98D9A-08EE-4173-95D6-AFEA3C5A478BQ34786248-7F14FF18-8340-4E74-A84D-99A2D3DFAFD0Q35018901-80470D7B-738E-4FE1-8A2E-076468BC948BQ35183100-1E702CA8-3B23-417E-9B60-483B5E8C0F5FQ35200425-3C0C1456-AD04-4722-A437-7F191758787DQ35872419-41A1D6B2-B329-4FF1-8F8F-E3E07EAFB266Q35992165-0EAD2740-9CE9-436B-8172-A4BE350E6B1FQ36429636-15828D61-4A35-4952-9D67-465117482C2BQ36850467-F0CF8FA2-9E50-4EE3-93FD-A733B8B3921BQ36900093-3A358EF5-A2C0-4744-BC95-483537C1B33EQ37353937-13179F71-0DC8-4A49-9B06-461A06DAA194Q38006606-EAD445BB-F94C-473B-A611-F259413A570CQ38348786-3A2CE471-2AF7-43B6-B34A-F102E754CE0BQ38567366-AC7A0DD5-65B2-48D4-BDDD-91A0F8DA3733Q38608775-E5874F2D-6964-4149-8542-C22CA9DB2582Q38814109-A337FD65-6B36-4823-8349-321A00E6E947
P2860
Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@ast
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@en
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@nl
type
label
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@ast
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@en
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@nl
prefLabel
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@ast
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@en
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@nl
P2093
P2860
P356
P1476
Analysis of transforming activ ...... eling factor hBRM/hSNF2 alpha.
@en
P2093
H Nishihara
K Nagashima
P2860
P304
P356
10.1073/PNAS.061036798
P407
P577
2001-03-01T00:00:00Z